Key facts
- Notable investors include Peiyang Begonia Fund, Tianjin Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Beyonpep
- ·The full record, as it builds
Funding rounds
No funding rounds for Beyonpep are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beyonpep
Developer of nucleic-acid delivery technologies designed for therapeutic and research applications. The company uses an artificial intelligence-based design system to create peptide-based delivery carriers with high biocompatibility, targeted delivery efficiency, and suitability for transporting diverse nucleic acids such as mRNA, DNA, and siRNA, enabling biopharmaceutical researchers and developers to conduct more effective, customizable, and physiologically relevant nucleic acid delivery studies.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2022
- Website
- beyonpep.com/
- Ownership
- Privately Held (backing)
Beyonpep doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beyonpep shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beyonpep in its N-PORT filings yet. We sweep new filings monthly.